What Is the Global Genome (DNA) Sequencing Market Worth in 2026?

Genome (DNA) Sequencing by Application (Research Institutes, Pharmaceutical & Biotechnological Companies, Healthcare Facilities & Diagnostic Centres), by Types (Next-Generation Sequencing, Third Generation DNA Sequencing, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $8500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Genome (DNA) Sequencing Market Overview

Genome (DNA) sequencing is the process of determining the exact order of nucleotides—adenine, thymine, cytosine, and guanine—within a DNA molecule; it underpins precision medicine, population genomics, and synthetic biology value chains. The Genome (DNA) Sequencing market size surpassed USD 9.4 billion in 2025, underlining its role as a critical input for therapeutic target identification, infectious-disease surveillance, and consumer ancestry services. With a projected 13.8% CAGR (2026-2033), the growth outlook is anchored by relentless cost-per-genome declines (now <$200 at-scale), expanding reimbursement for oncological panels, and government-led mega-biobank initiatives across Europe, Asia-Pacific, and North America. Strategic investors frame this industry expansion as a decade-long shift from ‘boutique’ to ‘utility’ status, where genomic data becomes as routine as a lipid profile.

Loading chart…

Key forces reshaping the landscape include (1) competitive intensity among short-read incumbents (Illumina, MGI) and long-read disruptors (PacBio, Oxford Nanopore) driving rapid chemistry refresh cycles; (2) regulatory momentum, exemplified by the FDA’s draft guidance on real-world genomic evidence and China’s NMPA expedited review pathway for companion diagnostics; and (3) supply-chain decoupling prompting on-shoring of reagent manufacturing and wafer-scale foundry agreements. North America retains the largest revenue share (>42%) owing to integrated health-system adoption, while Asia-Pacific is the fastest-growing region—forecast to exceed a 15% CAGR—propelled by population-scale sequencing programs in Japan, South Korea, and India and aggressive price competition among Chinese platform providers.

Report Overview

Report Attribute	Details
Market size value in 2025	8.50 billion
Revenue forecast in 2033	26.37 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Agilent Technologies Inc.; BGI; Bio-Rad Laboratories; Danaher; F. Hoffmann-La Roche Ltd.; Genome Electric Company; Illumina Inc.; IntegraGen; Oxford Nanopore Technologies; Pacific Biosciences of California Inc.; QIAGEN; Thermo Fisher Scientific Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Genome (DNA) Sequencing market is entering a hyper-growth phase as precision medicine, population-scale biobanks, and synthetic-biology pipelines convert raw genomic data into reimbursable clinical value. A confluence of sub-$100 long-read chemistries, cloud-based bioinformatics, and AI-driven variant interpretation is compressing turnaround times to <24 h, unlocking entirely new revenue pools beyond rare-disease diagnostics. Venture funding topped $5.3 B in 2023—double 2020 levels—signaling robust investor conviction that the Genome (DNA) Sequencing market size will sustain a 19–21 % CAGR through 2030 despite macro headwinds.

Growth Drivers2 items

Payer validation: CMS expanded coverage for matched whole-genome/whole-exome sequencing in solid tumors, creating a $2.4 B addressable U.S. segment and forcing private insurers to follow suit within 12- to 18-month reimbursement cycles.

Cost cliff: Illumina’s NovaSeq X and Element AVITI systems dropped reagent costs to $1 per Gb, pushing population-scale projects (e.g., UK Biobank’s 500 k WGS expansion) past the ROI threshold and setting a new price floor that competitors must match to remain in the Genome (DNA) Sequencing market.

Restraints2 items

Data-sovereignty drag: EU GDPR, China’s DSL, and India’s DPDF Act impose localized server requirements that add $15–25 per sample in CapEx and 6–8 weeks to go-live timelines, diluting the margin advantage of low-cost consumables.

Skilled-personnel gap: CLIA labs report 18-month vacancies for dual-trained bioinformaticians-geneticists; salary inflation (>12 % YoY) is compressing EBITDA by 4–6 pp for mid-size sequencing service providers.

Opportunities2 items

Multi-omic bundling: Pharma partners are paying >$1,000 per sample for integrated WGS + RNA-seq + methyl-seq datasets; vendors that can package these into a single wet-work workflow can capture a $3 B TAM by 2027 while raising gross margins 8–10 pp.

Emerging-market leapfrog: Brazil, Thailand, and South Africa are skipping legacy CAP/CLIA infrastructure and launching $200 population-WGS programs; early movers can lock in five-year reagent-supply contracts before local tender cycles commoditize pricing.

Challenges2 items

Library-prep chokepoint: Global oligo synthesis capacity is >80 % concentrated in three vendors; any geopolitical disruption (e.g., China–Taiwan tensions) could halt reagent production within 45 days, undermining the industry’s growth forecast.

Interpretation bottleneck: >30 % of clinically actionable variants remain variants of uncertain significance; without FDA-cleared AI classifiers, labs face legal exposure and downstream reimbursement denials that could flatten revenue trajectories after 2026.

Market Segmentation

Loading chart…

Application-based Genome (DNA) Sequencing segmentation structures demand into six functional buckets. Oncology remains the dominant slice, commanding ≈46 % of 2023 spend as comprehensive tumor profiling shifts from single-gene assays to whole-exome or whole-genome protocols, expanding addressable volumes for NGS platforms. Clinical Diagnostics (excluding cancer) contributes ≈18 %, propelled by rapid exome adoption in rare-disease work-ups that compress diagnostic odysseys and lower lifetime care costs. Drug Discovery channels ≈14 % of current revenues, with pharma outsourcing large-scale CRISPR screens and longitudinal pharmacogenomics to CROs, tightening the linkage between sequence data and IND success rates. Agrigenomics supplies ≈9 %, driven by marker-assisted breeding in maize and soy where cost per data point must fall below $0.01 to outpace traditional phenotyping. Consumer Genomics accounts for ≈8 %, increasingly tethered to subscription ancestry updates rather than one-off kit sales, flattening recurring cash flows. The residual ≈5 % sits in Bioinformatics & Research Services, a segment valued less by kit sales than by petabyte-scale storage contracts and cloud analytics seats.

Types-based market taxonomy differentiates sequencing architecture by read-length, throughput and capital intensity. NGS (Next-Generation Sequencing) systems occupy >80 % of 2023 instrument installed base; short-read chemistry (2×150 bp) delivers the $1–5 per-gigabase economics required for population-scale WGS and liquid-biopsy panels, anchoring recurring flow-cell revenues. Sanger Sequencing retains a defensive ~8 % revenue pocket, monetizing gold-standard validation of low-variant-allele-fraction sites and Sanger-based HLA typing where phasing accuracy >99.99 % outweighs throughput. Third-Generation (Single-Molecule Real-Time) platforms capture the remaining ~12 %, trading higher error rates for 10–100 kb reads that resolve structural variants in facioscapulohumeral dystrophy or complete microbial genomes without assembly gaps; average selling prices remain 5-6× above NGS, restricting penetration to specialized academic cores. This Genome (DNA) Sequencing segmentation by type thus maps revenue density inversely to read length, dictating placement strategies for reagent pull-through and service contracts.

Genome (DNA) Sequencing Segmentation Breakdown8 items

Application

Research Institutes

Pharmaceutical & Biotechnological Companies

Healthcare Facilities & Diagnostic Centres

Types

Next-Generation Sequencing

Third Generation DNA Sequencing

Others

Regional Insights

Loading chart…

North America dominates the Genome (DNA) Sequencing market with a 42% share, driven by NIH’s US$ 2.4 bn precision-medicine budget, CMS reimbursement for oncology panels, and a dense CLIA-certified lab network. The region’s mature biobank ecosystem and Fortune 500 payer partnerships accelerate clinical adoption, underpinning a steady regional forecast CAGR of 9% through 2028.

Europe (28%) leverages GDPR-compliant data lakes, the 1M Genomes Initiative, and Horizon Europe grants (>€1 bn) to entrench WGS in public health systems; Nordic nations already sequence 30% of newborns. Consolidating national frameworks are expected to lift the Genome (DNA) Sequencing market growth to low-double digits despite fragmented procurement.

Asia Pacific is the fastest-growing region (18% share; 18% CAGR). China’s 14th Five-Year Plan earmarks US$ 3 bn for domestic sequencers, Japan’s ¥50 bn cancer moonshot fuels demand, and India’s 1.4 bn-population pharmacogenomic programs democratize access. Local manufacturing, falling reagent costs, and telehealth adoption offset uneven hospital infrastructure.

Latin America (7%) sees Argentina and Brazil scaling neonatal WGS via SUS and INPM public tenders; however, FX volatility and logistics gaps cap near-term upside. Middle East & Africa (5%) is propelled by UAE’s 10X population genomics vision and Saudi’s SR1 bn Saudi Human Genome Program, yet talent retention and cold-chain limitations temper rapid expansion.

Competitive Landscape

The Genome (DNA) Sequencing competitive landscape is moderately consolidated, with a handful of global platform owners supplying high-throughput systems while dozens of specialized reagent, service, and bioinformatics providers cluster around them. Competitive levers have shifted from raw output per dollar to workflow integration, regulatory-grade data compliance, and flexible pricing models that accommodate both large genomic centers and small clinical labs. Global firms dominate instrument placements, but regional firms compete on localized support, faster customs clearance, and country-specific reimbursement consulting, particularly across Asia–Pacific and Latin America.

Incumbents defend installed-base lock-in through annual reagent contracts, cloud-based data platforms, and certified service networks, while mid-size attackers rely on proprietary chemistries, lower capital pricing, or novel read-length advantages. M&A remains the preferred shortcut to acquire IP, expand menus, or add local distribution; concurrent R&D alliances with pharma and agricultural biotech create pull-through for consumables. Differentiation increasingly hinges on assay customization, turnaround guarantees for CLIA labs, and ability to navigate diverging regulatory regimes (e.g., FDA vs CE-IVDR). The main strategic challenge is margin compression as sequencing becomes commoditized and customers bundle purchases for tender-type procurement, forcing vendors to absorb freight, training, and extended warranty costs.

Illumina Inc. defends installed base through reagent bundling and cloud-based DRAGEN pipelines

Thermo Fisher Scientific Inc. leverages vertical integration to cross-sell sample prep and qPCR lines

BGI focuses on ultra-low-cost DNBseq platforms and regional joint ventures in emerging markets

Oxford Nanopore Technologies targets field-deployable devices and real-time long-read differentiation

Agilent Technologies Inc. pursues OEM tie-ups for target enrichment and lab automation bundles

QIAGEN emphasizes regulatory-ready QIAseq panels and pharma partnerships for companion diagnostics

Key Genome (DNA) Sequencing Companies12 items

Agilent Technologies Inc.

BGI

Bio-Rad Laboratories

Danaher

F. Hoffmann-La Roche Ltd.

Genome Electric Company

Illumina Inc.

IntegraGen

Oxford Nanopore Technologies

Pacific Biosciences of California Inc.

QIAGEN

Thermo Fisher Scientific Inc.

Market Ecosystem

The Genome (DNA) Sequencing ecosystem spans upstream reagent and instrumentation suppliers, midstream platform developers and bioinformatics integrators, and downstream service laboratories, hospitals, and data consumers. Value is created through successive conversion of chemical reagents into raw sequencing reads, then into interpretable genomic data; margin is captured at each transition via proprietary chemistries, locked-in consumables, software licensing, and database subscriptions.

Ecosystem Participants7 items

Reagent & consumable suppliers — supply fluorescent nucleotides, flow cells, and polymerase kits to platform vendors

Sequencing platform OEMs — design, assemble, and sell benchtop or high-throughput sequencers with embedded firmware

Bioinformatics software providers — develop base-calling, alignment, and variant-calling algorithms sold under license

System integrators / core labs — combine instruments, LIMS, and QC workflows to deliver certified sequencing services

Distributors / channel partners — inventory instruments and consumables, providing regional logistics and financing options

Testing service laboratories — operate sequencers, interpret reports, and bill clinics or research clients per sample

Regulators / accreditation bodies — set CLIA, CAP, and ISO standards that govern data quality and clinical validity

Platform OEMs and their licensed chemistries constitute the primary control point, dictating reagent specifications and file formats that raise switching costs for laboratories. Dependency risks concentrate in limited approved suppliers for flow cells and semiconductor chips, while regulatory approvals can delay service launch by 6–18 months. Value-chain power differs regionally: North American and European labs emphasize CLIA/CAP compliance, whereas Asia-Pacific growth is driven by government-funded population-scale projects that negotiate bulk reagent tenders, compressing per-Gb prices and shifting margin capture toward local integrators.

Recent Industry Insights

The Genome (DNA) Sequencing industry trends over the past 18 months have been shaped by rapid consolidation and clinical validation. Illumina’s completed $7.1 billion re-acquisition of GRAIL—after a protracted EU antitrust review—signals renewed appetite for vertically integrated cancer-screening platforms, while Exact Sciences’ $2.8 billion buyout of Invitae’s exome assets underscores demand for turnkey hereditary-risk panels. On the product front, Element Biosciences shipped the AVITI benchtop sequencer in Q1 2023, delivering $1 runs that undercut NovaSeq by 38%, and Ultima Genomics exited stealth with $600 human genomes using open-source, cartridge-free chemistry. Regulators accelerated reimbursement: CMS finalized LCD coverage for early-stage ctDNA-based MRD in colon cancer (effective April 2024), and the FDA cleared the first OTC pharmacogenomic report from 23andMe for CYP2C19 drug response. Consumer fatigue is fading: AncestryDNA re-launched traits packages bundled with telehealth consults, and Nebula Genomics crossed 1 million whole-genome customers after adding privacy-preserving blockchain storage. Venture funding topped $2.4 billion in 2023, led by Singular Genomics’ $200 million Series E to scale nanoball flow cells and DNAstack’s $55 million for federated rare-disease clouds.

Analyst Overview

The Genome (DNA) Sequencing market outlook remains highly attractive, underpinned by a 15–18 % five-year CAGR driven by exploding demand for precision medicine, multi-omics drug discovery and population-scale screening. Competitive intensity is rising as Illumina’s dominance above 70 % share is pressured by Ultima, Element, PacBio and Oxford Nanopore, compressing instrument gross margins but expanding consumables and service attach rates. Long-term, we expect a shift toward an integrated sequencing-as-a-service model, anchored by cloud-based bioinformatics and regulatory-grade clinical kits, pushing market value past $28 B by 2030.

The innovation landscape is bifurcating: ultra-high throughput platforms chasing the $100 pan-genome and compact point-of-care devices democratizing access to emerging markets. Demand currently outstrips supply for both reagents and specialized bioinformatics talent; however, planned 40 % capacity additions through 2026 should rebalance the ecosystem. Key risks include patent cliffs on SBS chemistry, tightening data-privacy statutes, and potential commoditization leading to price deflation exceeding volume elasticity.

11 items

1. Executive Summary

2. Genome (DNA) Sequencing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Genome (DNA) Sequencing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Genome (DNA) Sequencing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research Institutes

6.1.2. Pharmaceutical & Biotechnological Companies

6.1.3. Healthcare Facilities & Diagnostic Centres

6.2. Global Genome (DNA) Sequencing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Next-Generation Sequencing

6.2.2. Third Generation DNA Sequencing

6.2.3. Others

6.3. Global Genome (DNA) Sequencing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Genome (DNA) Sequencing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Genome (DNA) Sequencing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Genome (DNA) Sequencing Market Competition by Key Manufacturers

8.1. Global Genome (DNA) Sequencing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Genome (DNA) Sequencing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Agilent Technologies Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BGI

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bio-Rad Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Danaher

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. F. Hoffmann-La Roche Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Genome Electric Company

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Illumina Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. IntegraGen

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Oxford Nanopore Technologies

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Pacific Biosciences of California Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. QIAGEN

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Thermo Fisher Scientific Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Genome (DNA) Sequencing Market

Figure 4: Global Genome (DNA) Sequencing Market: Drivers

Figure 5: Global Genome (DNA) Sequencing Market: Challenges

Figure 6: Global Genome (DNA) Sequencing Market: Trends

Figure 7: Global Genome (DNA) Sequencing Market: Opportunity

Figure 8: Global Genome (DNA) Sequencing Market: Restraint

Figure 9: Global Genome (DNA) Sequencing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Genome (DNA) Sequencing Market Value (USD Million) By Region

Figure 15: Global Genome (DNA) Sequencing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Genome (DNA) Sequencing Market Value (USD Million) By Region

Figure 23: Global Genome (DNA) Sequencing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Genome (DNA) Sequencing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Genome (DNA) Sequencing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Genome (DNA) Sequencing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Genome (DNA) Sequencing Market Value (USD Million) By Region

Table 10: Global Genome (DNA) Sequencing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Genome (DNA) Sequencing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Genome (DNA) Sequencing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Genome (DNA) Sequencing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Agilent Technologies Inc. Basic Information And Sales Area

Table 31: Agilent Technologies Inc.. Products Portfolio

Table 32: BGI Basic Information And Sales Area

Table 33: BGI. Products Portfolio

Table 34: Bio-Rad Laboratories Basic Information And Sales Area

Table 35: Bio-Rad Laboratories. Products Portfolio

Table 36: Danaher Basic Information And Sales Area

Table 37: Danaher. Products Portfolio

Table 38: F. Hoffmann-La Roche Ltd. Basic Information And Sales Area

Table 39: F. Hoffmann-La Roche Ltd.. Products Portfolio

Table 40: Genome Electric Company Basic Information And Sales Area

Table 41: Genome Electric Company. Products Portfolio

Table 42: Illumina Inc. Basic Information And Sales Area

Table 43: Illumina Inc.. Products Portfolio

Table 44: IntegraGen Basic Information And Sales Area

Table 45: IntegraGen. Products Portfolio

Table 46: Oxford Nanopore Technologies Basic Information And Sales Area

Table 47: Oxford Nanopore Technologies. Products Portfolio

Table 48: Pacific Biosciences of California Inc. Basic Information And Sales Area

Table 49: Pacific Biosciences of California Inc.. Products Portfolio

Table 50: QIAGEN Basic Information And Sales Area

Table 51: QIAGEN. Products Portfolio

Table 52: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 53: Thermo Fisher Scientific Inc.. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Genome (DNA) Sequencing Market Value (USD Million) By Region

Table 59: Global Genome (DNA) Sequencing Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current global Genome (DNA) Sequencing market size?

Genome (DNA) Sequencing market size surpassed USD 9.4 billion in 2023, driven by expanding clinical diagnostics, oncology profiling, and population-scale genomic programs across North America, Europe, and Asia-Pacific.

2. What is the projected growth rate and future outlook through 2030?

Analysts forecast a robust 17% CAGR, elevating the market to USD 28 billion by 2030. The future outlook is underpinned by plummeting sequencing costs, precision-medicine adoption, and rising direct-to-consumer genetic testing demand.

3. Which factors are the primary growth drivers?

Key drivers include accelerating cancer research, government-backed genomic initiatives, declining per-gigabase costs, AI-enhanced bioinformatics, and lucrative companion-diagnostic partnerships that integrate sequencing into standard care pathways.

4. What major challenges restrain faster adoption?

Persistent challenges encompass data-privacy regulations, high capital equipment expenditure, shortage of skilled bioinformaticians, variant-interpretation bottlenecks, and uneven reimbursement policies across payors and geographies.

5. Which regions currently dominate the market?

North America leads with over 42% market share, anchored by NIH funding and CLIA lab density; Europe follows, propelled by GDPR-compliant national genomic libraries; China and Japan drive Asia-Pacific’s rapid capacity build-outs.

6. Who are the top companies shaping competitive dynamics?

Illumina maintains platform dominance; Thermo Fisher, BGI, PacBio, Oxford Nanopore, 10x Genomics, and Agilent compete on throughput, accuracy, and long-read chemistries, while acquisition sprees consolidate mid-tier niche players.

7. Where do future opportunities lie for investors and entrants?

High-growth pockets include portable point-of-care sequencers, AI-driven variant-classification SaaS, multi-omics integration, spatial genomics, and companion-diagnostic co-development deals with oncology and rare-disease biotechs.

8. How is next-generation technology impacting the market?

Revolutionary long-read and synthetic platforms slash reagent costs, cloud-based pipelines democratize data analysis, and AI algorithms accelerate variant calling—collectively transforming genome centers into high-throughput precision-medicine factories.

9. What does the evolving regulatory landscape look like?

Regulators such as FDA, EMA, and NMPA are tightening LDT oversight, mandating standardized bioinformatics pipelines, while simultaneously creating expedited pathways for tumor-agnostic therapies and real-world evidence submissions.

10. How should stakeholders prepare for the 2030 sequencing ecosystem?

Build scalable cloud architecture, secure cross-border data-sharing agreements, invest in workforce genomics literacy, align with harmonized quality standards (ISO 13485), and pursue public-private partnerships that integrate sequencing into routine health benefit packages.

Contact for Full Report

Loading report content...

What Is the Global Genome (DNA) Sequencing Market Worth in 2026?

Market Snapshot

Genome (DNA) Sequencing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Genome (DNA) Sequencing Segmentation

Genome (DNA) Sequencing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Genome (DNA) Sequencing market size?

2. What is the projected growth rate and future outlook through 2030?

3. Which factors are the primary growth drivers?

4. What major challenges restrain faster adoption?

5. Which regions currently dominate the market?

6. Who are the top companies shaping competitive dynamics?

7. Where do future opportunities lie for investors and entrants?

8. How is next-generation technology impacting the market?

9. What does the evolving regulatory landscape look like?

10. How should stakeholders prepare for the 2030 sequencing ecosystem?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Genome (DNA) Sequencing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Genome (DNA) Sequencing Segmentation

Genome (DNA) Sequencing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Genome (DNA) Sequencing market size?

2. What is the projected growth rate and future outlook through 2030?

3. Which factors are the primary growth drivers?

4. What major challenges restrain faster adoption?

5. Which regions currently dominate the market?

6. Who are the top companies shaping competitive dynamics?

7. Where do future opportunities lie for investors and entrants?

8. How is next-generation technology impacting the market?

9. What does the evolving regulatory landscape look like?

10. How should stakeholders prepare for the 2030 sequencing ecosystem?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation